Updated:
AMAG Pharmaceuticals
AMAG Pharmaceuticals develops and commercializes specialty pharmaceutical products. The company markets an intravenous iron compound for treating iron...
Overview
AMAG Pharmaceuticals develops and commercializes specialty pharmaceutical products. The company markets an intravenous iron compound for treating iron deficiency anemia in adult patients with chronic kidney disease and an oral rinse for managing oral mucositis in the US. AMAG seeks to expand its portfolio with additional commercial-stage specialty pharmaceuticals.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Waltham
Corporate office
Waltham, MA, United States
Sector focus
Frequently asked questions
What happened to AMAG's legacy drug portfolio?
AMAG's legacy commercial products included Makena, a preterm-birth therapy that the FDA withdrew in 2023 after confirmatory trials failed to show benefit, and Feraheme, an anemia treatment still on the market. Prior to the Altaris acquisition, AMAG divested its Cord Blood Registry service and the MuGard cancer-support product line as part of a broader restructuring.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: